New applications of disease genetics and pharmacogenetics to drug development.
Publication
, Journal Article
Roses, AD; Saunders, AM; Lutz, MW; Zhang, N; Hariri, AR; Asin, KE; Crenshaw, DG; Budur, K; Burns, DK; Brannan, SK
Published in: Curr Opin Pharmacol
February 2014
TOMMORROW is a Phase III delay of onset clinical trial to determine whether low doses of pioglitazone, a molecule that induces mitochondrial doubling, delays the onset of MCI-AD in normal subjects treated with low dose compared to placebo. BOLD imaging studies in rodents and man were used to find the dose that increases oxygen consumption at central regions of the brain in higher proportion than activation of large corticol regions. The trial is made practical by the use of a pharmacogenetic algorithm based on TOMM40 and APOE genotypes and age to identify normal subjects at high risk of MCI-AD between the ages of 65-83 years within a five year follow-up period.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Curr Opin Pharmacol
DOI
EISSN
1471-4973
Publication Date
February 2014
Volume
14
Start / End Page
81 / 89
Location
England
Related Subject Headings
- Thiazolidinediones
- Pioglitazone
- Pharmacology & Pharmacy
- Pharmacogenetics
- Humans
- Genotype
- Drug Design
- Cognitive Dysfunction
- Clinical Trials, Phase III as Topic
- Brain
Citation
APA
Chicago
ICMJE
MLA
NLM
Roses, A. D., Saunders, A. M., Lutz, M. W., Zhang, N., Hariri, A. R., Asin, K. E., … Brannan, S. K. (2014). New applications of disease genetics and pharmacogenetics to drug development. Curr Opin Pharmacol, 14, 81–89. https://doi.org/10.1016/j.coph.2013.12.002
Roses, Allen D., Ann M. Saunders, Michael W. Lutz, Nanyin Zhang, Ahmad R. Hariri, Karen E. Asin, Donna G. Crenshaw, Kumar Budur, Daniel K. Burns, and Stephen K. Brannan. “New applications of disease genetics and pharmacogenetics to drug development.” Curr Opin Pharmacol 14 (February 2014): 81–89. https://doi.org/10.1016/j.coph.2013.12.002.
Roses AD, Saunders AM, Lutz MW, Zhang N, Hariri AR, Asin KE, et al. New applications of disease genetics and pharmacogenetics to drug development. Curr Opin Pharmacol. 2014 Feb;14:81–9.
Roses, Allen D., et al. “New applications of disease genetics and pharmacogenetics to drug development.” Curr Opin Pharmacol, vol. 14, Feb. 2014, pp. 81–89. Pubmed, doi:10.1016/j.coph.2013.12.002.
Roses AD, Saunders AM, Lutz MW, Zhang N, Hariri AR, Asin KE, Crenshaw DG, Budur K, Burns DK, Brannan SK. New applications of disease genetics and pharmacogenetics to drug development. Curr Opin Pharmacol. 2014 Feb;14:81–89.
Published In
Curr Opin Pharmacol
DOI
EISSN
1471-4973
Publication Date
February 2014
Volume
14
Start / End Page
81 / 89
Location
England
Related Subject Headings
- Thiazolidinediones
- Pioglitazone
- Pharmacology & Pharmacy
- Pharmacogenetics
- Humans
- Genotype
- Drug Design
- Cognitive Dysfunction
- Clinical Trials, Phase III as Topic
- Brain